Jeito Capital Supports Groundbreaking Advances in Cancer Therapy

Jeito Capital Champions New Era in Cancer Treatment

In an exciting development for the biopharma sector, Jeito Capital has co-led an impressive €164.5 million ($181.4 million) oversubscribed Series D financing round for Alentis Therapeutics. This significant investment aims to propel the clinical development of innovative Anti-Claudin-1 antibody-drug conjugates (ADCs) specifically targeting solid tumors.

Ongoing Commitment to Alentis Therapeutics

This latest round builds on Jeito's previous investments in Alentis Therapeutics during its Series B and Series C funding rounds. Jeito Capital's consistent financial backing showcases its commitment to supporting burgeoning companies through pivotal milestones in their growth journey. The ongoing partnership signifies a shared vision for developing cutting-edge therapies that address critical medical needs.

New Investments Join the Fray

The current financing round also welcomed several notable new investors, including OrbiMed, Frazier Life Sciences, Longitude Capital, Catalio Capital, Piper Heartland Healthcare Capital, and Avego Bioscience Capital. Existing partners, such as Novo Holdings and RA Capital Management, remained integral contributors, underlining the strong collaborative ethos surrounding Alentis's mission.

Advancements in Clinical Programs

Jeito’s investment will primarily focus on advancing Alentis' two pioneering Anti-CLDN1 ADC programs. Recently, the FDA cleared an Investigational New Drug (IND) application for the lead program, ALE.P02, which integrates a tubulin inhibitor. The company is set to initiate Phase 1/2 clinical trials aimed at advanced or metastatic CLDN1+ squamous solid tumors soon.

Aiming for Future Trials

The second program, ALE.P03, which incorporates a topoisomerase I inhibitor, is also on track, with first-in-human trials slated for the upcoming year. These developments highlight Alentis's commitment to aggressively moving its pipeline forward, bolstered by substantial financial support.

A Vision for Transformative Healthcare

Dr. Rafaèle Tordjman, the founder and CEO of Jeito Capital, expressed enthusiasm regarding the current financing round: "Supporting Alentis in this new venture reinforces our strategy of fostering innovative companies. The strength of Alentis’s pipeline is indeed promising, and we're eager to contribute our expertise in facilitating their growth and success."

Dr. Roberto Iacone, CEO of Alentis Therapeutics, also shared excitement regarding the financing: "This initiative underscores the transformative potential of CLDN1 antibody-drug conjugates for treating solid tumors. We are eager to execute our ambitious development strategy and share clinical data with the community within the next year or so."

About Jeito Capital

Jeito Capital stands as a leading global Private Equity fund dedicated to enhancing patient benefits through groundbreaking medical innovations. With a primary focus on biopharma, Jeito empowers its portfolio companies through expert guidance, significant capital investments, and a commitment to building market leaders across various therapeutic areas. Currently managing €534 million, Jeito’s presence spans across both Europe and the United States, reflecting its strong international approach to healthcare innovation.

About Alentis Therapeutics

Alentis Therapeutics has established itself as a pioneering company in clinical-stage biotechnology, primarily developing treatments for CLDN1+ tumors. These tumors represent a previously untapped target with considerable implications for combating cancer and fibrotic diseases. Headquartered in Switzerland, Alentis has garnered respect in the biopharma community through its innovative approaches and groundbreaking research originating from esteemed institutions. Alentis is dedicated to advancing its pipelines by leveraging the latest scientific advancements.

Frequently Asked Questions

What is the significance of Jeito Capital's investment in Alentis Therapeutics?

Jeito Capital's investment bolsters Alentis's ability to develop transformative therapies targeting solid tumors, demonstrating confidence in their innovative pipeline.

What are the key projects being funded through the Series D financing?

The funding is primarily aimed at advancing two breakthrough Anti-CLDN1 ADC programs, which are crucial in treating cancer, particularly in CLDN1 positive tumors.

Who are the main investors involved in this financing round?

The financing was led by OrbiMed, with participation from Jeito Capital, Novo Holdings, Frazier Life Sciences, and several other prominent firms.

When will the clinical trials for the new therapies begin?

Phase 1/2 clinical trials for the lead program ALE.P02 are set to commence in Q1 2025, with another program planned to initiate trials in the same year.

What is the overall goal of Alentis Therapeutics?

Alentis aims to develop cutting-edge therapies that address critical unmet medical needs, focusing specifically on CLDN1+ tumors and related conditions.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.